Modulation of neural stem cells and neural progenitor cells
AssigneeNeuroNova AB
InventorsPer Lindquist, Alex Mercer, Harriet Rönnholm, Lilian Wikström
Life of this patent
Estimating the term…
Abstract
The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder.
Claims16
A method of alleviating a symptom of a disorder of the nervous system in a patient comprising administering an S1P, LPA or EDG receptor agonist to induce neural stem cell (NSC) proliferation in vivo to a patient suffering from the disorder of the nervous system, wherein the S1P, LPA or EDG receptor agonist is S1P, LPA, or a combination thereof, and wherein the S1P, LPA or EDG receptor agonist is administered to achieve a target tissue concentration of 0.1 nM to 10 μM, thereby alleviating a symptom of a disorder of the nervous system.
A method of enhancing neural stem cell proliferation in a patient suffering from a central nervous system disorder comprising administering an S1P, LPA or EDG receptor agonist to said patient, wherein the S1P, LPA or EDG receptor agonist or a combination thereof is administered in an amount of 0.1 ng/kg/day to 10 mg/kg/day.
Dependencies are inferred from the claim text.